Physician profile
Zelda Fleming
NPI 1376068320
$1,507.21
in general payments reported to CMS, 2019-2025
17 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $56.83 · 2024: $952 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $416.84 | 2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $384.20 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $136.10 | 2022-2024 | Repatha, Otezla |
| Vanda Pharmaceuticals INC. | $100.00 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $97.48 | 2024 | Xarelto |
| Abbott Laboratories | $71.30 | 2024-2025 | Freestyle Libre 3, Eterna |
| Viiv Healthcare Company | $69.36 | 2024-2025 | Apretude |
| Pfizer INC. | $43.34 | 2024-2025 | |
| Lilly USA, LLC | $37.40 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $23.23 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.08 | 2025 | Xifaxan |
| Dexcom, INC. | $20.58 | 2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $20.22 | 2024 | |
| Glaxosmithkline, LLC. | $19.28 | 2023 | Shingrix |
| Astellas Pharma US INC | $17.19 | 2024 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $15.29 | 2025 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $14.32 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zelda Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.